Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
 over alleged Violations of Securities Laws announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Dec. 07, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Pennsylvania on behalf of certain purchasers of shares of Lannett Company, Inc. (NYSE:LCI) over alleged Securities Laws Violations by Lannett Company.
Investors, who purchased shares of Lannett Company, Inc. (NYSE:LCI) in August 2013 or earlier and currently hold any of those NYSE:LCI shares, have also certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Lannett Company, Inc. was fixing, maintaining, and controlling prices of digoxin in violation of Connecticut antitrust laws, that Lannett Company, Inc. was allocating and dividing customers and territories with competitors relating to the sale of digoxin in violation of Connecticut antitrust laws, that Lannett Company, Inc.’s anticompetitive practices subjected Lannett to heightened regulatory scrutiny, including possible investigation by the Connecticut Office of the Attorney General ("CTAG"), and that as a result of the foregoing, Lannett Company, Inc.'s public statements were allegedly materially false and misleading at all relevant times.
Those who purchased Lannett Company, Inc. (NYSE:LCI) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
[email protected]
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
